Increased operational expenses and reduced cash reserves were cited. Roivant Sciences reports improved EPS for the second ...

Roivant Sciences Ltd (ROIV) showcases robust financial health with $5.4 billion in cash and no debt, while navigating competitive pressures and strategic opportunities.

Good day and thank you for standing by. Welcome to the Roivant second-quarter 2024 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I ...

Vivek Ramaswamy, 39, is a multimillionaire former biotech executive, who will lead the newly-established Department of ...

Indian-American entrepreneur and author Vivek Ramaswamy, known for founding Roivant Sciences, has become a prominent figure ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Roivant Sciences (ROIV – Research Report) yesterday. The company’s shares closed yesterday at $11.64. According to TipRanks, Werber is a 5-star ...

Vivek Ramaswamy will lead, together with Elon Musk, the Department of Government Efficiency (D.O.G.E) in the Donald Trump ...

Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.26 per share a year ago. These ...

Roivant's high valuation stems from its strong cash position, promising drug pipeline, Techbio assets, and strategic partnerships, making it a compelling buy. Recent sales of Telavant and ...

BASEL, Switzerland - Roivant Sciences (NASDAQ:ROIV) announced the promising results of the Phase 1b ATMOS study for mosliciguat, a potential first-in-class inhaled therapy for... Roivant (Nasdaq ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Roivant Sciences (ROIV – Research Report) today. The company’s shares ...